128 related articles for article (PubMed ID: 37164107)
1. 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial: Should dose intensification be discontinued or should accelerated schemes remain an important area of clinical research?
Arcidiacono F; Anselmo P; Casale M; Trippa F
Radiother Oncol; 2023 Aug; 185():109688. PubMed ID: 37164107
[No Abstract] [Full Text] [Related]
2.
Cooke SA; de Ruysscher D; Reymen B; Lambrecht M; Fredberg Persson G; Faivre-Finn C; Dieleman EMT; Lewensohn R; van Diessen JNA; Sikorska K; Lalezari F; Vogel W; van Elmpt W; Damen EMF; Sonke JJ; Belderbos JSA
Radiother Oncol; 2023 Apr; 181():109492. PubMed ID: 36706958
[TBL] [Abstract][Full Text] [Related]
3. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
[TBL] [Abstract][Full Text] [Related]
4. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Møller DS; Nielsen TB; Brink C; Hoffmann L; Lutz CM; Drøgemüller Lund M; Hansen O; Schytte T; Khalil AA; Knap MM; Nyhus CH; Ottosson W; Sibolt P; Borissova S; Josipovic M; Persson G; Appelt AL
Radiother Oncol; 2017 Aug; 124(2):311-317. PubMed ID: 28688525
[TBL] [Abstract][Full Text] [Related]
6. [What dose escalation in the treatment of locally advanced non-small cell lung cancer?].
Thureau S; Mallet R; Gouel P; Modzelewski R; Vera P
Cancer Radiother; 2022 Oct; 26(6-7):890-893. PubMed ID: 36075830
[TBL] [Abstract][Full Text] [Related]
7. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J; De Ruysscher D; Sonke JJ; Damen E; Sikorska K; Reymen B; van Elmpt W; Westman G; Fredberg Persson G; Dieleman E; Bjorkestrand H; Faivre-Finn C; Belderbos J
Radiother Oncol; 2019 Feb; 131():166-173. PubMed ID: 30327236
[TBL] [Abstract][Full Text] [Related]
8. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
9. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
Feng M; Kong FM; Gross M; Fernando S; Hayman JA; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1228-34. PubMed ID: 19251094
[TBL] [Abstract][Full Text] [Related]
10. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
11. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study.
van Baardwijk A; Bosmans G; van Suylen RJ; van Kroonenburgh M; Hochstenbag M; Geskes G; Lambin P; De Ruysscher D
Radiother Oncol; 2008 Apr; 87(1):55-8. PubMed ID: 18328584
[TBL] [Abstract][Full Text] [Related]
12. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET in planning radiation treatment of non-small cell lung cancer: where exactly is the tumor?
Dahele MR; Ung YC
J Nucl Med; 2007 Aug; 48(8):1402; author reply 1403. PubMed ID: 17673427
[No Abstract] [Full Text] [Related]
14. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
15. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
16. A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.
La Fontaine M; Vogel W; van Diessen J; van Elmpt W; Reymen B; Persson G; Westman G; De Ruysscher D; Belderbos J; Sonke JJ
Radiother Oncol; 2018 May; 127(2):259-266. PubMed ID: 29709378
[TBL] [Abstract][Full Text] [Related]
17. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
[TBL] [Abstract][Full Text] [Related]
18. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
Chin AL; Kumar KA; Guo HH; Maxim PG; Wakelee H; Neal JW; Diehn M; Loo BW; Gensheimer MF
Clin Lung Cancer; 2018 Sep; 19(5):e581-e588. PubMed ID: 29759331
[TBL] [Abstract][Full Text] [Related]
20. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
Gagel B; Reinartz P; Demirel C; Kaiser HJ; Zimny M; Piroth M; Pinkawa M; Stanzel S; Asadpour B; Hamacher K; Coenen HH; Buell U; Eble MJ
BMC Cancer; 2006 Mar; 6():51. PubMed ID: 16515707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]